Concepedia

Publication | Open Access

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

DOIFull Paper Access

141

Citations

33

References

2009

Year

Nicole Mittmann, H. Au, D. Tu, Christopher J. O’Callaghan, Pierre K. Isogai, Christos S. Karapetis, John Zalcberg, W.K. Evans, M. J. Moore, J. Siddiqui,
JNCI Journal of the National Cancer Institute

Abstract

The incremental cost-effectiveness ratio of cetuximab over best supportive care alone in unselected advanced colorectal cancer patients is high and sensitive to drug cost. Incremental cost-effectiveness ratios were lower when the analysis was limited to patients with wild-type KRAS tumors.

References

YearCitations

Page 1